Martins Francis

Martins Francis supports clients through data-driven analysis to inform both federal and state healthcare policies using his quantitative skills and analytic insight.

He is a highly enthusiastic and process-oriented Healthcare data analyst with broad understanding of healthcare datasets, such as Medicare FFS claims data, Medicare Advantage enrollment data and other public survey data. Competent in working with data to perform high quality analysis for insights that translate into meaningful business decisions. He has expert knowledge in advanced statistics, mathematics, and analytics, with an excellent understanding of business operations and analytics tools for effective analyses of data.

Prior to joining Avalere, he worked as an HR analyst for Access Bank where he was involved in analyzing and reporting recruitment data to inform the bank’s recruitment policies.Martins has a MS in global health policy and management with a concentration in economics and analytics from Brandeis University and a BS in statistics from Plateau State Polytechnic in Nigeria.

Authored Content

The COVID-19 pandemic has created significant challenges for all Americans, particularly for its most vulnerable populations, including the elderly and people with disabilities in Medicare. The Centers for Medicare & Medicaid Services (CMS) recently reported that 21% of fee-for-service (FFS) Medicare enrollees have stated they are forgoing non-COVID-19 related care due to the pandemic. Avalere conducted analyses to determine if a similar decrease in utilization is occurring in Medicare Advantage (MA) and assess the potential impact of deferred care on MA enrollees and plans.

New analysis from Avalere finds that Medicare beneficiaries are more likely to receive Part D autoimmune drugs and less likely to receive Part B autoimmune drugs from providers who are part of Accountable Care Organizations (ACOs) in the Medicare Shared Savings Program (MSSP) compared to non-ACO providers.

Avalere analysis finds that Medicare fee-for-service (FFS) patients with an RA diagnosis and conditions associated with undermanaged disease have 121% higher medical costs than other RA patients. Part D costs were 30% higher for those with undermanaged disease than for other RA patients.

As COVID-19 deaths increase, the FDA is evaluating and considering approval of treatments more quickly, but the rush to find treatment options is creating new access considerations for patients and providers.

An Avalere analysis finds that Medicare Part D plans allow $0 cost-sharing for select vaccines just 4% of the time, likely affecting immunization uptake.

Avalere analysis finds that new users account for a large share of Medicare spending on opthalmic medications.